Join
Live feed
·
PRReleasevia Quantisnow
NervGen Pharma Corp. logo

NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury

ByQuantisnow·Wall Street's wire, on your screen.
NGEN· NervGen Pharma Corp.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NGEN (NervGen Pharma Corp.) and more on Quantisnow.